On April 7, 2024, Fosun Pharma (SSE: 600196, HKEX: 02196) released its 2024 ESG and Sustainability Report (referred to as the "Report"), marking the 17th consecutive year the Company has demonstrated its ESG practices and achievements in environmental protection, social responsibility, and corporate governance to stakeholders.

Finloop Finance Technology Holding Limited (“Finloop”), an AI-driven one-stop institutional wealth management platform incubated by Fosun Wealth Holdings under Fosun, announced that it has become one of the strategic enterprises of the Office for Attracting Strategic Enterprises (“OASES”) of the Government of Hong Kong Special Administrative Region. This milestone represents a significant advancement in Fosun Wealth Holdings’ fintech strategy and a solid step forward for Finloop in deepening its foothold in wealth management market in Hong Kong.

On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”) held its 2024 annual results presentation in Shanghai. The results presentation was attended by Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu and Xu Xiaoliang, Co-CEOs of Fosun International, Gong Ping, CFO of Fosun International, and a number of institutional investors and analysts.

The year 2024 concluded successfully, thanks to the collective efforts of all Fosuners. Looking back on the past year, we sustained steady growth momentum and demonstrated robust resilience in the face of global economic fluctuations and market challenges.

(Hong Kong, Shanghai, 30 March 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2024 (the “Reporting Period”).

Fosun International (HKEX stock code: 00656, hereinafter referred to as "Fosun International", "Fosun", or the "Company") has successfully completed the refinancing of a USD 870 million equivalent syndicated loan due on March 28, 2025. Of this amount, USD 675 million equivalent was secured through a newly arranged syndicated loan. Consistent with the Company’s past practices, the new syndicated loan includes a greenshoe option, allowing additional banks to participate.

(March 25, 2025, Shanghai, China) On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK),a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 (“the Reporting Period”).

Shanghai, China, March 24, 2025 – Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius’ total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached RMB820.5 million, a 50.3% YoY growth, with a net profit margin of 14.3%, up by 41.6% YoY. This marks Henlius' second consecutive year of full-year profitability following its first profitable year in 2023. The increasing commercial sales of core products have been a key driver of profitability, with total product sales revenue reaching approximately RMB4.9335 billion, an increase of 8.3% YoY. Additionally, the company’s annual R&D expenditure reached RMB1.8405 billion, representing an increase of 28.4% YoY.

Hong Kong, March 19, 2025 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK; together with its subsidiaries collectively referred to as the “Group”), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), Injectables, alongside other complementary offerings, announced its audited consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).